deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT03744676

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)

A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting

Sponsor: Bristol-Myers Squibb

Conditions Immune System Disorder Immunoproliferative Disorders Lymphatic Diseases Lymphoma Lymphoma, B-Cell Lymphoma, Large B-Cell, Diffuse Lymphoma, Non-Hodgkin Lymphoproliferative Disorders Neoplasms Neoplasms by Histologic Type
Interventions lisocabtagene maraleucel
Updated 30 times since 2018 Last updated: Feb 25, 2025 Started: Nov 29, 2018 Primary completion: Sep 22, 2023 Completion: Sep 22, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Immune System Disorder and Immunoproliferative Disorders, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 30 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Dec 2019 · 30 days · monthly snapshot~Dec 2019 – ~Jan 2020 · 31 days · monthly snapshot~Jan 2020 – ~Feb 2020 · 31 days · monthly snapshot~Feb 2020 – ~May 2020 · 3 months · monthly snapshot~May 2020 – ~Jun 2020 · 31 days · monthly snapshot~Jun 2020 – ~Aug 2020 · 2 months · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~May 2021 · 2 months · monthly snapshot~May 2021 – ~Sep 2021 · 4 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Nov 2023 · 7 months · monthly snapshot~Nov 2023 – ~Jan 2024 · 2 months · monthly snapshot~Jan 2024 – ~Jul 2024 · 6 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 16 months · monthly snapshot

Change History

30 versions recorded

  1. Mar 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Mar 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Nov 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 25 earlier versions

  1. Apr 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Feb 2022 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  6. May 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

  7. Mar 2021 — May 2021 [monthly]

    Recruiting PHASE2

  8. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  9. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  10. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  11. Jun 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  12. May 2020 — Jun 2020 [monthly]

    Recruiting PHASE2

  13. Feb 2020 — May 2020 [monthly]

    Recruiting PHASE2

  14. Jan 2020 — Feb 2020 [monthly]

    Recruiting PHASE2

  15. Dec 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  16. Nov 2019 — Dec 2019 [monthly]

    Recruiting PHASE2

  17. Oct 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  18. Sep 2019 — Oct 2019 [monthly]

    Recruiting PHASE2

  19. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  20. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE2

  21. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  22. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  23. Mar 2019 — May 2019 [monthly]

    Recruiting PHASE2

  24. Jan 2019 — Mar 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  25. Dec 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Nov 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Juno Therapeutics, a Subsidiary of Celgene
Data source: Juno Therapeutics, a Subsidiary of Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States , Cincinnati, United States , Dallas, United States , Denver, United States , East Brunswick, United States , Eugene, United States , Greenville, United States , Indianapolis, United States , Lancaster, United States , Los Angeles, United States and 13 more locations